Crohn'
Conditions
Interventions
Infliximab maintenance therapy for 48 weeks in, Racol daily nutritional interventions during the study period as a target intake of 800kcal per day, in the implementation group nutrition therapy is us
Sponsors
Graduate School of Medical Sciences, Kyushu University
Oita Red Cross Hospital Takano Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with Crohn's disease in remission underwent infliximab maintenance therapy that meets all of the following criteria: It is intended for. (1) Administered every 8 weeks infliximab, the patient is less than or equal to 150 CDAI (2) Patient age at the time of registrationis at least 20 years of age, consent has been obtained for participation in this study
Exclusion criteria
Exclusion criteria: This is true even if one of the following are excluded from the scope. (1)Patients with bowel obstruction (2)Patients with short bowel syndrome (3)Patients with advanced liver and kidney failure (4)Patients with abnormal glucose metabolism, such as severe diabetes (5)Patients with congenital disorders of amino acid metabolism (6)Patients with milk protein allergy (7)Patients with stoma (8) Other patients attending physician has determined inappropriate test
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative non-relapse rate at 48 weeks (Definition of relapse; as if CDAI was more than 150 and had increased more than 70 from the previous value. Cases of relapse were defined as patients who fulfill the definition of relapse at least once in determination of CDAI at every four weeks.) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)CRP concentration in Blood 2)QOL assessment by SF-36 Other | — |
Countries
Japan
Contacts
Public ContactKoji Ikegami
Graduate School of Medical Sciences, Kyushu University Medical and Clinical Science
Outcome results
None listed